Do you want to read an article? Please log in or register.
Neuropsychiatric syndromes of multiple sclerosis
Multiple SclerosisAnxiety and DepressionBipolar DisorderPsychosis and Schizophrenia
Related content
Multiple Sclerosis
Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis
N Engl J Med.
Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G1, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team
doi: 10.1056/NEJMoa1608889.
Multiple Sclerosis
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study
Lancet Neurol.
Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA
doi: 10.1016/
Multiple Sclerosis
Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome
JAMA Neurol.
van der Vuurst de Vries RM, Mescheriakova JY, Wong YYM, Runia TF, Jafari N, Samijn JP, de Beukelaar JWK, Wokke BHA, Siepman TAM, Hintzen RQ
doi: 10.1001/jamaneurol.
Aging and Cognitive FunctionsMultiple Sclerosis
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial
Lancet Neurol.
Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J
doi: 10.1016/S1474-4422
Multiple Sclerosis
Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
J Neurol.
Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).
doi: 10.1007/s00415-019-09563-y.
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes
Ann Neurol.
Chung KK, Altmann D, Barkhof F, Miszkiel K, Brex PA, O'Riordan J, Ebner M, Prados F, Cardoso MJ, Vercauteren T, Ourselin S, Thompson A, Ciccarelli O, Chard DT
doi: 10.1002/ana.25637.
RECOMMENDED
Multiple Sclerosis
The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Brain.
Sorensen PS, Sellebjerg F, Hartung HP, Montalban X, Comi G, Tintoré M
doi: 10.1093/brain/awaa145.
RECOMMENDED
Multiple Sclerosis
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L
doi: 10.1016/S1474-4422(19)30391-6.